Clinical Trial

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Study acronym: Sightspire
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2028-09-12 -> 2028-11-15 2026-05-27
minor Completion pushed: 2028-10-12 -> 2028-11-15 2026-05-27
notable Trial sites expanded: 53 -> 56 locations 2026-04-28
notable Trial sites expanded: 45 -> 53 locations 2026-03-31
Trial Details
NCT Number NCT06847542
Lead Sponsor Hoffmann-La Roche
Collaborators: Genentech, Inc.
Conditions Neovascular Age-related Macular Degeneration
Enrollment 250 participants
Start Date 2025-11-27
Primary Completion 2028-11-15 (estimated)
Study Completion 2028-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-24